Top Melbourne, Victoria Healthtech Companies (32)
For over 20 years, we’ve been redefining how life- and mission-critical industries enable, control, and monitor digital identities to deliver fast access, improve security, and ensure compliance. Customer success is our DNA, which is why we’re trusted by the most prominent healthcare and enterprise organizations in 45 countries.
InterSystems has been the information engine behind the world's most important applications in healthcare, business and government for over 40 years. Our software products provide advanced data management, integration, and analytics technologies used daily by millions of people in 80+ countries.
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong SAR, Türkiye, Brazil, Mexico, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India. For more information, visit www.bupa.com
Medtronic is a global healthcare solutions company operating in approximately 160 countries. We are committed to improving lives through our medical technologies, services, and solutions. Since our beginning, 60 years ago, our Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. The Mission is our ethical framework and inspirational goal guiding our day-to-day work. It reminds us that our efforts are transforming millions of lives each year. To meet the needs of patients and healthcare professionals around the globe, we operate from more than 370 locations in approximately 160 countries.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX)
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. To learn more, visit www.modernatx.com. This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products. We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).
The Atmo Gas Capsule is a world first patented solution to accurately profile the gases within the gut, leading to better diagnosis and treatment of gastrointestinal disorders.
Mable is a health-tech platform where people looking for disability and aged care support connect with independent support workers in their community. As one of Australia’s fastest-growing scale-ups, we think big to spearhead change in our sector. We're passionate about inclusivity and giving choice and control back to those who need it. Mable launched in 2014 when co-founder Peter Scutt teamed up with friend and colleague Tony Charara after struggling to find the right home care solution for his parents. Today, Australia’s largest and most diverse community of independent support workers has provided over 13 million hours of support on Mable so everyone can live their kind of independence. #mykindofindependence
Welcome to Cabrini Health Cabrini is owned and operated by the Missionary Sisters of the Sacred Heart of Jesus who came to Australia in 1948 to take over the management of a 45-bed community hospital named St Benedict’s. Cabrini now has more than 800 beds and a comprehensive range of health services. There are acute facilities at Malvern and Brighton. The Cabrini Institute supports education and research, in order to continually improve the quality of care and educate tomorrow’s health professionals. Cabrini Technology provides an innovative, independent information and healthcare technology service to organisations throughout Australasia and has headquarters in Mount Waverley. More recently, Cabrini has established an Asylum Seeker and Refugee Health Hub in Brunswick, which provides access to a range of health services for people seeking asylum and newly arrived refugees. Cabrini is a not-for-profit health service and all surpluses are used to develop our services and facilities to provide the best possible care for patients and families. Cabrini supports and operates a number of other programs for disadvantaged people in our community. Patient care is the primary focus of our work and at the heart of all we do
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the health of their skin. Those working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. Imagine what the rest of our team of 134,000 people at 260 companies in more than 60 countries across the world is accomplishing. We redefine what it means to be a big company in today’s world. Social Media Community Guidelines: http://www.jnj.com/social-media-community-guidelines
Palla Pharma Limited is one of three licensed poppy processors in Australia, and the only Australian-owned company. It is one of only three companies globally that is vertically integrated from poppy growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally-sustainable extraction and purification manufacturing process which allows the company to deliver a highly competitive pricing platform. The company’s strategy is to secure access to regulated downstream narcotics markets to leverage its reliable, cost-competitive upstream raw material capability.
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
HotDoc is Australia's largest and most trusted patient engagement platform. We take pride in helping over 21,000 practitioners connect with more than 9 million patients. The HotDoc platform includes: online bookings, recalls, reminders, check-in, place in queue, online processing of repeat prescription requests, and Inform (a tool designed to encourage patients to take a more proactive interest in preventative health and chronic disease management). HotDoc also provides free monthly webinars where practice managers, GPs, nurses and medical receptionists can earn CPD points. With over 20,000 registrations last year alone, HotDoc's webinar series is the highest attended healthcare webinar series in Australia. Interested in a career at HotDoc? Visit our careers page: https://apply.workable.com/hotdoc/
PKG Health believes every person with a neurological condition deserves to live their best life every day. We leverage the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Its lead product, the Parkinson's KinetiGraph®(PKG® or Personal KinetiGraph® in the US), has been developed by neurologists at the world-renowned Florey Institute of Neuroscience in Melbourne, Australia. The PKG® enables the precise monitoring, quantification and reporting of movement patterns of neurological diseases including bradykinesia, dyskinesia, tremor and immobility. Our PKG technology: • Technically de-risked and established in market – over 6,000,000 hours of continuous Parkinson’s monitoring delivered to date, representing more than 25,000 patient PKGs • Changes clinical decisions more than 50% of the time • Boasts significant key opinion leader support • Is underpinned by robust clinical validation and regulatory clearance through FDA 510(k) in the USA, CE mark in Europe, TGA Class IIA ARTG 236583 listed The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson’s disease continuum. GK continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure the efficacy of new and advanced therapies for one of the world’s most widespread movement disorders. For further information, please visit our website, www.pkgcare.com
Advancing the world’s transition to AI-supported healthcare.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.
Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.
Smileyscope is a multi-award winning digital therapeutics company with proprietary technology that reframes medical procedures using choreographed virtual-reality (VR) experiences to help reduce patient pain and anxiety, and improve the overall patient experience. Our vision is to expand the frontiers of patient-centered care, improving the moments that matter most. Smileyscope VR is the first regulatory body approved VR product for medical use and is clinically proven to reduce patient pain, anxiety and the need for restraints. It is being used by clinicians across a range of medical procedures such as needle procedures, wound dressings, anaesthetic induction, using nitrous oxide, awaiting theatre, and plaster cast applications/removals. Smileyscope VR has been designed by clinicians, for clinicians. It is very easy to learn and fits seamlessly into the clinical workflow. It has been incredibly well received by clinicians, patients and caregivers. “It’s a game changer. Patients are getting better care and needing less sedation and pain medication” - Anaesthetist “My child has had over 300 procedures. This was the first time he has not cried” - Parent of a 5yr old patient “Smileyscope brings out the joy in work. It can turn a traumatic procedure into a pleasant one” – Emergency Paediatrician Smileyscope is operating in Australia, USA, UAE, Europe and UK. Smileyscope VR is being used in leading hospitals in Australia, USA and UAE. For non-USA based queries, please contact [email protected] to learn more. For USA based queries, please contact [email protected] to learn more
Work Your Passion. Live Your Purpose.
